New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
06:34 EDTJAZZJazz Pharmaceuticals trades at attractive risk/reward, says Piper Jaffray
Piper Jaffray believes Jazz Pharmaceuticals' acquisition of the U.S. rights to Defitelio makes the company's long-term growth story even more attractive. Piper says Jazz shares trade at an attractive risk/reward and it reiterates an Overweight rating on the name with a $200 price target.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
16:16 EDTJAZZJazz Pharmaceuticals initiates rolling NDA submission for defibrotide
Subscribe for More Information
December 9, 2014
08:31 EDTJAZZJazz, Concert say Phase 1 JZP-386 evaluation not done at highest dosage
Subscribe for More Information
December 8, 2014
07:29 EDTJAZZUBS to hold investor trip
Subscribe for More Information
07:18 EDTJAZZUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use